Figure 2From: A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancerSurvival outcomes after erlotinib treatment. Kaplan–Meier estimates of progression-free survival (a) and overall survival (b). Dot censored case at the data cut-off point.Back to article page